WO2002038208A2 - Dispositif et procede pour arreter de fumer - Google Patents

Dispositif et procede pour arreter de fumer Download PDF

Info

Publication number
WO2002038208A2
WO2002038208A2 PCT/US2001/051239 US0151239W WO0238208A2 WO 2002038208 A2 WO2002038208 A2 WO 2002038208A2 US 0151239 W US0151239 W US 0151239W WO 0238208 A2 WO0238208 A2 WO 0238208A2
Authority
WO
WIPO (PCT)
Prior art keywords
nicotine
chamber
solution
person
oral
Prior art date
Application number
PCT/US2001/051239
Other languages
English (en)
Other versions
WO2002038208A9 (fr
WO2002038208A3 (fr
Inventor
Barbara S. Fox
Original Assignee
Recovery Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recovery Pharmaceuticals, Inc. filed Critical Recovery Pharmaceuticals, Inc.
Priority to JP2002540788A priority Critical patent/JP2004512907A/ja
Priority to CA002427283A priority patent/CA2427283A1/fr
Priority to AU2002234179A priority patent/AU2002234179A1/en
Priority to EP01985209A priority patent/EP1331960A2/fr
Publication of WO2002038208A2 publication Critical patent/WO2002038208A2/fr
Publication of WO2002038208A3 publication Critical patent/WO2002038208A3/fr
Publication of WO2002038208A9 publication Critical patent/WO2002038208A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47G—HOUSEHOLD OR TABLE EQUIPMENT
    • A47G21/00—Table-ware
    • A47G21/18—Drinking straws or the like
    • A47G21/183—Drinking straws or the like with means for changing the flavour of the liquid
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A24F42/20—Devices without heating means
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A24F42/60—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0038—Straws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J15/00—Feeding-tubes for therapeutic purposes
    • A61J15/0011—Feeding-tubes for delivery of nourishment to the mouth; Mouth pieces therefor

Definitions

  • the field of the present invention is pharmacology. More specifically, the invention relates to smoking cessation methods and aids that provide a non-irritating form of nicotine to the user as well as the oral and tactile stimulation of smoking.
  • Cigarette smoking is the leading cause of preventable disease and death in the United States. Each year, over 400,000 adults die from tobacco-related diseases (A Report of the Surgeon General. Rockville. MD: Public Health Service (2000)). In addition to health risks facing smokers themselves, the annoyance and risks of second-hand smoke are receiving increased attention. Although airlines, workplaces, and restaurants often ban smoking, almost 88% of non-smokers have detectable blood levels of nicotine metabolites (Morbidity and Mortality Weekly, November 5, 1999). Environmental tobacco smoke remains a preventable health hazard for smokers' co-workers and family members (A Report of the Surgeon General, Rockville, MD: Public Health Service (2000)).
  • nicotine nasal spray see, e.g., AU 66441
  • nicotine inhaler see, e.g., U.S. Patent Nos. 4,920,989 and 4,953,572
  • sustained-release bupropion hydrochloride see, e.g., Jorenby et al., N. Engl. J. Med., 340:685-91(1999)
  • Other examples of smoking cessation aids include nicotine nose drops (see, e.g., U.S. Patent No. 4,579,858); nicotine lozenges (see, e.g., U.S. Patent Nos. 4,806,35 and 5,549,906); smoke-free cigarettes (see, e.g., U.S.
  • nicotine gum and lozenges can cause high localized nicotine concentration in the mouth, which tastes unappealing, and the gum may be difficult to chew.
  • chewing gum or eating lozenges may appear unprofessional.
  • Nicotine patches may irritate the skin, and some smokers are dissatisfied with the lack of rapid nicotine absorption from the patch. Nicotine nasal sprays may irritate the nose and throat. More importantly, none of these smoking cessation aids simulates the tactile sensations or hand-to-mouth behaviors that form an integral part of the smoker's addiction. Studies have shown that sensory aspects affect smoking behavior and cigarette cravings as much as nicotine intake does.
  • Cigarette smoking involves a hand-to-mouth ritual that may be repeated over 70,000 times per year. Since smoking cessation requires giving up a highly ingrained habitual motion as well as giving up nicotine, an effective smoking cessation aid should address the behavioral components of smoking as well as providing nicotine replacement therapy.
  • a smoking cessation aid should give the smoker the comfort of an oral and tactile ritual, while at the same time supplying nicotine.
  • a smoking cessation device that is too similar to a conventional cigarette and provides oral sensations and tactile stimuli that too closely mimic tobacco smoking may not be ideal.
  • a smoker using such a device might find it too easy to relapse into cigarette smoking (see, e.g., Schneider et al., Addiction, 91:1293-1306 (1996)).
  • a smoking cessation aid that provides the synergistic combination of nicotine plus oral and tactile stimuli, while not too closely approximating a conventional tobacco cigarette, seems most desirable.
  • U.S. Patent No. 5,284,163 discloses a smoke-free cigarette substitute comprising a nicotine granulate in a tubular sleeve.
  • the end of the sleeve contains a gum plug, which is bitten off and held in the mouth as chewing gum.
  • nicotine granulate is pulled into the mouth and can be chewed into the gum, thus dispensing nicotine into the oral cavity.
  • This product may possess the drawbacks of nicotine chewing gum described above. Also, as with any smoke-free cigarette, using it may approximate the behavioral aspects of smoking so closely that smoking cessation becomes more difficult.
  • U.S. Patent Nos. 4,284,089 and 4,813,437 disclose non-pyrolytic devices shaped like ordinary cigarettes and containing porous polymer plugs holding volatile liquid nicotine. Drawing on the device delivers nicotine vapors to a person's lungs. However, these devices are unable to deliver sufficient uniform doses of nicotine. Additionally, the vaporizable nicotine tastes unpleasant and is unstable, such that the devices have a very short shelf life.
  • U.S. Patent No. 6,041,789 (Bankert et al.) addresses some of these problems with a non- pyrolytic cigarette substitute that delivers a nicotine-simulating vapor mixture with a cigarettelike taste and aroma.
  • the device contains a volatile nicotinomimetic agonist and volatile palatability enhancing agents.
  • this device does not actually deliver nicotine.
  • the cigarette-like structure, taste, and aroma may make the device so similar to a conventional cigarette that smokers using it as a cessation aid are likely to relapse.
  • 02190178 discloses a smoke-free tobacco "perfume solution” that may be vaporized and administered through a "tubular flexible casing.”
  • the solution may present health risks due to the carcinogens and irritating particulates contained in tobacco.
  • using the device may approximate the actual tastes, smells, and motions of cigarette smoking so closely that smoking cessation is made more difficult.
  • U.S. Patent No. 5,293,883 discloses a non-pyrolytic cigarette containing two tobacco-filled chambers, which house unburned and pre-burned tobacco, and a mouth filter that holds nicotine-filled ampules that release pure liquid nicotine into a person's mouth when the person breaks them open by biting or manually crushing the mouth filter.
  • This device provides nicotine and a cigarette-like taste, but it may suffer from the drawbacks of liquid nicotine described above. Additionally, as discussed above, the device presents the health hazards of tobacco and may make smoking cessation more difficult by too closely approximating actual tobacco cigarettes.
  • a smoking cessation aid that synergistically provides an easily controllable nicotine dose in a non-irritating form along with a delivery device that supplies the oral and tactile stimulation that smokers crave, without too closely approximating actual cigarette smoking.
  • the present invention solves the foregoing problems by providing a smoking cessation aid that delivers nicotine in non-irritating solution form and offers the oral and tactile stimulation that smokers crave. Drawing a nicotine solution through the device and into the mouth is similar to the accustomed hand-to-mouth behavior of smoking. However, because the nicotine is delivered as a solution rather than as inhaled vapors, using the present smoking cessation aid is different enough from actual smoking that behavioral similarities should not encourage smokers to relapse. Nicotine delivered as a solution also does not irritate the oral cavity as do inhaled vapors from a nicotine spray.
  • the invention provides an oral nicotine delivery device comprising a tubular chamber, a nicotine granulate contained within the chamber, and a retainer in the chamber.
  • the chamber has a first end suitable for taking in a liquid from an external source and a second end suitable for oral application of suction.
  • the retainer prevents release of the nicotine granulate and liquid from the first end of the chamber.
  • the retainer is fixed proximal to the first end of the chamber. In other embodiments, the retainer is transportable toward the second end of the chamber with the nicotine granulate and the liquid when suction is applied to the second end of the chamber.
  • the nicotine granulate comprises coated particles of powdered nicotine.
  • the nicotine particles are coated to enhance palatability.
  • the nicotine granulate comprises particles of powdered nicotine that are incorporated in spheres comprising at least one material selected from the group consisting of sugar, starch, acacia, sodium alginate, carbomer, cellulose, dextrotes, ethyl cellulose, methyl cellulose, and povidone.
  • the tubular chamber contains from about 1 milligram to about 40 milligrams of nicotine. In yet another embodiment, the tubular chamber contains from about 4 milligrams to about 12 milligrams of nicotine.
  • the nicotine is preferably selected from the group consisting of levo nicotine, dextro nicotine, racemic mixtures thereof, and pharmaceutically acceptable salt forms thereof.
  • a solution of nicotine is formed when the liquid enters the chamber and contacts the nicotine.
  • the solution is a suspension.
  • the invention provides a method for reducing the incidence of tobacco smoking by a person. The method comprises orally administering nicotine to the person using the device according to the previous aspect of the invention. The person applies oral suction to the second end of the chamber, such that the liquid enters the chamber from the external source through the first end of the chamber. The liquid and the nicotine are then delivered through the second end of the chamber into the mouth of the person.
  • a single dose of nicotine administered to the person is from about 1 milligram to about 40 milligrams of nicotine.
  • the dose administered is from about 4 milligrams to about 12 milligrams of nicotine.
  • the total daily dose of nicotine administered to the person is from about 4 milligrams to about 144 milligrams of nicotine.
  • the blood level of nicotine in the person after administration of the nicotine is at least about 5 nanograms of nicotine per 1 milliliter of blood.
  • the blood level of nicotine in the person after administration of the nicotine is from about 10 nanograms to about 50 nanograms of nicotine per 1 milliliter of blood.
  • a solution of nicotine is formed when the liquid enters the chamber and contacts the nicotine.
  • the solution has an acidic pH.
  • the invention provides an oral nicotine delivery device comprising a tubular chamber, a nicotine solution contained within the chamber, and a retainer.
  • the chamber has a first end suitable for taking in a liquid or a gas from an external source and a second end suitable for oral application of suction.
  • the retainer is for preventing release of the nicotine solution from the first end of the chamber.
  • the nicotine solution is delivered through the second end of the chamber when oral suction is applied to the second end of the chamber.
  • a liquid enters the chamber from an external source through the first end of the chamber when oral suction is applied to the second end of the chamber.
  • the liquid and the nicotine solution are then delivered from the device through the second end of the chamber.
  • a gas enters the chamber from an external source through the first end of the chamber when oral suction is applied to the second end of the chamber.
  • the nicotine solution is then delivered from the device through the second end of the chamber.
  • the tubular chamber approximates the size and shape of a conventional cigarette. In alternative embodiments, the tubular chamber approximates the size and shape of a conventional drinking straw.
  • the retainer is transportable toward the second end of the chamber with the nicotine solution when suction is applied to the second end of the chamber.
  • the nicotine solution is a nicotine suspension.
  • the nicotine suspension comprises a nicotine granulate.
  • the nicotine granulate comprises coated particles of powdered nicotine, and in some preferred embodiments, the nicotine particles are coated to enhance palatability.
  • the nicotine granulate comprises particles of powdered nicotine that are incorporated in spheres comprising at least one material selected from the group consisting of sugar, starch, acacia, sodium alginate, carbomer, cellulose, dextrotes, ethyl cellulose, methyl cellulose, and povidone.
  • the nicotine solution contains from about 1 milligram to about 40 milligrams of nicotine. In a particular embodiment, the nicotine solution contains from about 4 milligrams to about 12 milligrams of nicotine. In a particular embodiment, the chamber contains from about 1 milliliter to about 5 milliliters of the nicotine solution.
  • the nicotine in the nicotine solution is preferably selected from the group consisting of levo nicotine, dextro nicotine, racemic mixtures thereof, and pharmaceutically acceptable salts thereof. In some embodiments, the nicotine solution has an acidic pH. In some embodiments, the nicotine solution further comprises a flavoring.
  • the invention provides a method for reducing the incidence of tobacco smoking by a person.
  • the method comprises orally administering nicotine to the person using the device according to the previous aspect of the invention.
  • the person applies oral suction to the second end of the chamber, such that the nicotine solution is delivered from the chamber through the second end of the chamber into the mouth of the person.
  • a single dose of nicotine administered to the person is from about 1 milligram to about 40 milligrams of nicotine. In a particular embodiment, the single dose administered is from about 4 milligrams to about 12 milligrams of nicotine. In some preferred embodiments, the total daily dose of nicotine administered to the person is from about 4 milligrams to about 144 milligrams of nicotine. In some embodiments, the blood level of nicotine in the person after administration of the nicotine solution is at least about 5 nanograms of nicotine per 1 milliliter of blood. In some preferred embodiments, the blood level of nicotine in the person after administration of the nicotine solution is from about 10 nanograms to about 50 nanograms of nicotine per 1 milliliter of blood. In a preferred embodiment, the nicotine solution is a nicotine suspension.
  • FIG. 1 is a diagrammatic representation of a frontal view of a nicotine delivery device of the invention that approximates the shape and size of a conventional drinking straw.
  • FIG. 2 is a diagrammatic representation of a frontal view of a nicotine delivery device of the invention that approximates the shape and size of a conventional cigarette.
  • the present invention provides smoking cessation methods and smoking cessation aids that deliver a nicotine solution through a tubular device to a user.
  • the advantage of delivering nicotine through a tubular device is that the oral and tactile sensations experienced by the user approximate the ingrained hand-to-mouth behaviors associated with smoking.
  • the device of the present invention offers the smoker oral and manual focus, which helps to alleviate cigarette cravings by providing an object for the smoker to manipulate and chew.
  • the device of the invention may approximate a conventional drinking straw in size and shape.
  • the device may approximate a conventional cigarette in size and shape.
  • the term "approximate” means that the device comprises an elongated tubular chamber 10, with a first end 12 adapted for drawing in air or liquid from an external source and a second end 14 adapted for the application of oral suction, and that the dimensions of the device are similar to the dimensions of a conventional drinking straw or a conventional cigarette.
  • the device approximates a conventional drinking straw in shape and size.
  • the chamber 10 is preferably from about 13 to about 20 centimeters long, with a diameter of from about 4 to about 8 millimeters.
  • the chamber 10 is from about 15 to about 17 centimeters long, with a diameter of from about 6 to about 7 millimeters.
  • the device approximates a conventional cigarette in shape and size.
  • the chamber 10 is preferably from about 7 to about 11 centimeters long, with a diameter of from about 7 to about 10 millimeters. More preferably, the chamber 10 is from about 8 to about 10 centimeters long, with a diameter of about 8 millimeters.
  • the tubular delivery devices of the present invention include, without limitation, devices such as those disclosed in U.S. Patent No. 5,718,681 (Manning) and U.S. Patent Nos. 5,780,058, 5,985,324, 5,989,590, 6,024,721, and 6,106,845 (Wong et al.).
  • Materials for making the tubular chamber 10 of the present invention may include, without limitation, paper, plastic such as propylene/styrene copolymers, polypropylene, high density polyethylene, low density polyethylene, ethylene vinyl acetate copolymer, and the like.
  • the tubular chamber 10 of the device of the present invention contains nicotine 16 that will be delivered to the user.
  • the nicotine 16 may be in any useful form, such as levo nicotine, dextro nicotine, or a racemic mixture thereof.
  • Pharmaceutically acceptable salt forms of nicotine are also suitable for use in the present invention.
  • suitable salt forms of nicotine include the dihydrochloride, sulfate, bitartrate, salicylate, hydrogen tartrate, and hemisulfate salts. Nicotine and its salt forms are commercially available, for example, from Sigma- Aldrich, St. Louis, MO.
  • the nicotine 16 is a granulate.
  • granulate means that the nicotine is in the form of a particulate such as grains or beads.
  • the size of the grains or beads preferably is small enough not to be felt as separate particles in the mouth, preferably less than about 200 micrometers in diameter.
  • the nicotine granulate comprises particles of powdered nicotine which have been coated according to standard techniques known in the art (see, e.g., Deasy, Crit Rev. Ther. Drug Carrier Systems, 8:39-89 (1991)).
  • the term "powdered” means composed of fine particles.
  • Glatt Air Technique (Ramsay, NJ) and Particle and Coating Technologies, Inc. (St. Louis, MO) provide particle coating services. Suitable coatings include, without limitation, hydroxy propyl cellulose, sugar, starch, polymer, resin, gum, wax, and fat.
  • the diameter of the nicotine particles before coating is preferably less than about 200 micrometers, more preferably from about 20 to about 100 micrometers, and still more preferably from about 40 to about 60 micrometers.
  • the nicotine granulate comprises particles of powdered nicotine that are incorporated into microspheres, which may be coated as described above.
  • suitable materials for the microspheres include, without limitation, sugar, starch, acacia, sodium alginate, carbomer, cellulose, dextrotes, ethyl cellulose, methyl cellulose, povidone, and mixtures thereof.
  • the microspheres may comprise a degradable composition.
  • the microspheres have a diameter of between about 300 micrometers and about 1000 micrometers, preferably between about 500 micrometers and about 600 micrometers.
  • U.S. Patent No. 5,939,100 discloses further examples of nicotine microspheres.
  • the coating on the nicotine particles or microspheres preferably is designed to mask the taste of the nicotine, and thus enhance palatability.
  • the coating is formulated such that most, but not all, of the nicotine taste is masked.
  • the advantage of such a formulation is that enough of the nicotine taste is masked that the nicotine particles are palatable, but enough nicotine taste remains that the user is aware that nicotine is being ingested.
  • the formulation may comprise both coated and uncoated particles.
  • the coating on the particles or microspheres also may be designed to achieve other functions, including, but not limited to, preventing clumping and preventing water absorption.
  • a single dose of nicotine 16 from the device of the present invention contains a therapeutically effective amount of nicotine.
  • single dose means the quantity of nicotine 16 provided in the chamber 10 and delivered to the user upon application of oral suction to the second end 14 of the chamber 10.
  • therapeutically effective amount means an amount sufficient to reduce a smoker's need for nicotine from burnt tobacco. This amount can be determined by the user's physician.
  • An advantage of the smoking cessation devices of the invention is their ability to deliver a large dose of nicotine when necessary, or a smaller dose of nicotine when appropriate. Preferably, from about 1 milligram to about 40 milligrams of nicotine are provided by the device.
  • Useful amounts include from about 1 milligram to about 5 milligrams, from about 4 milligrams to about 12 milligrams, from about 4 milligrams to about 20 milligrams, from about 5 milligrams to about 15 milligrams, from about 5 milligrams to about 20 milligrams, and from about 20 milligrams to about 40 milligrams of nicotine provided by the device in a single dose.
  • a smoker attempting to stop smoking may use the device of the present invention from about 1 to about 12 times per day, preferably from about 5 to about 12 times per day, such that a total daily dose of from about 1 milligram to about 480 milligrams, preferably from about 5 milligrams to about 480 milligrams, of nicotine is delivered, depending on perceived need.
  • Useful total daily doses include from about 1 milligram to about 60 milligrams, from about 4 milligrams to about 144 milligrams, from about 4 milligrams to about 240 milligrams, from about 5 milligrams to about 180 milligrams, from about 5 milligrams to about 240 milligrams, and from about 240 milligrams to about 480 milligrams of nicotine.
  • total daily dose means the quantity of nicotine delivered to the user during a 24-hour period.
  • Such a dosing regimen preferably provides a blood level of nicotine of at least about 5 nanograms of nicotine per milliliter of blood, with a maximum peak of about 60 nanograms of nicotine per milliliter of blood.
  • the blood level of nicotine in the user of the device is from about 10 nanograms to about 50 nanograms of nicotine per milliliter of blood. More preferably, the user's blood level of nicotine is about 20 nanograms of nicotine per milliliter of blood.
  • Blood levels of nicotine preferably may be measured by gas chromatography with nitrogen phosphorous detection as described, for example, by Jacob et al., J. Chromatography, 222: 61-70 (1981).
  • the dosing frequency may be adjusted so as to achieve a steady state concentration of nicotine in the blood.
  • the steady state blood levels of nicotine preferably fall within the preferred blood level ranges described above.
  • the quantities of nicotine described above are sufficient to deliver a therapeutically effective amount of nicotine into the user's metabolism, even after first-pass absorption by the liver. It will be understood by those skilled in the art that the preferred doses and blood levels of nicotine will vary according to the preferences, metabolism, and former smoking habits of the individual user of the smoking cessation aid of the present invention.
  • the nicotine granulate is delivered to the user as a nicotine solution.
  • solution refers to a liquid into which the nicotine is dissolved, or a suspension or emulsion of nicotine in a liquid. Delivery of nicotine as a solution provides several advantages. Swallowing the solution provides the oral stimulation that smokers crave. However, the solution does not irritate the oral cavity as does nicotine gum. Additionally, nicotine in solution form is absorbed in the body more slowly than nicotine from a nasal spray. Such slow absorption allows for less frequent dosing and provides less potential for abuse. Finally, delivery of liquid along with the nicotine prevents high local concentrations of nicotine, which may result in cramping, for example, when a nicotine capsule is swallowed.
  • the first end 12 of the chamber 10 is placed in contact with an external source of liquid and the user applies oral suction to the second end 14 of the chamber 10.
  • a liquid is drawn into the first end 12 of the chamber 10 from the external source.
  • the liquid then forms a suspension of the nicotine 16 granulate as it is drawn through the chamber 10, and the suspension is delivered through the second end 14 of the chamber 10 into the user's mouth.
  • Some or all of the nicotine 16 granulate also may dissolve in the liquid, such that the nicotine 16 is delivered as a solution.
  • WO 99/55371 discloses non-limiting nicotine solutions whose properties may be desirable for use with the present invention.
  • the external source of liquid to be drawn into the tubular chamber 10 of a device of the invention is preferably a beverage.
  • the beverage contains a flavoring, which helps to make the nicotine solution palatable. This is less crucial where the nicotine taste has already been masked by coating the particles of the nicotine granulate.
  • palatable means that the taste of the solution is tolerable to the user.
  • the beverage may comprise, but is not limited to, coffee, soda, sugar, fruit juice, carbonation, or ethyl alcohol, such as wine, beer, or hard liquor.
  • the beverage does not contain solids such as pulp.
  • the nicotine solution preferably has an acidic pH.
  • acidic pH means a pH of less than about 6.9.
  • the nicotine solution has a pH of less than about 5.5. Most preferably, the nicotine solution has a pH from about 2.0 to about 4.0. Flavorings such as coffee, alcohol, and fruit juice may be used to regulate the pH of the nicotine solution. For example, lime juice, cranberry juice, grapefruit juice, orange juice, tonic water, soda, and wine have pH's from about 2.0 to about 4.0, and beer, seltzer water, coffee, and have pH's less than about 6.9.
  • An advantage of the smoking cessation devices of the present invention is their compatibility with beverages that are acidic, as the majority of popular beverages are.
  • Existing smoking cessation devices such as nicotine gum and nicotine inhalers, may not be used in combination with acidic beverages because an alkaline environment is required for buccal absorption of the nicotine delivered by such devices. Acidic beverages must be avoided for a period of about one hour surrounding each use of a smoking cessation device relying on buccal absorption of nicotine. Thus, smokers attempting to use such devices to give up smoking must also avoid consuming a majority of beverages much of the time. In contrast, smokers using nicotine delivery devices of the invention, through which nicotine is orally ingested, may consume acidic beverages whenever they choose.
  • the tubular chamber 10 of the device of the present invention may comprise two or more lumens.
  • the multiple lumens provide a plurality of smaller cross-sectional flow paths, which help to optimize the flow velocity and flow volume of the liquid from the external source, thus assuring rapid, uniform, and complete delivery of the nicotine 16 contained within the chamber 10.
  • the nicotine 16 may be contained in one of the lumens, or in multiple lumens.
  • the multiple lumens may be of identical size or of different sizes.
  • the chamber 10 of the device of the present invention contains a pre- formulated solution of nicotine 16 such as, for example, a nicotine suspension.
  • a pre- formulated solution of nicotine 16 such as, for example, a nicotine suspension.
  • About 1 milliliter to about 40 milliliters of nicotine solution may be provided in the chamber.
  • Preferably, from about 1 milliliter to about 10 milliliters, most preferably from about 1 milliliter to about 5 milliliters, of solution are provided.
  • the preferred single doses of nicotine, total daily doses of nicotine, and nicotine blood levels are as described above for the nicotine granulate.
  • the user applies oral suction to the second end 14 of the chamber 10 of the device, such that a gas such as air is drawn through the first end 12 of the chamber 10 into the device.
  • a gas such as air is drawn through the first end 12 of the chamber 10 into the device.
  • the nicotine 16 solution contained in the chamber 10 is delivered through the second end 14 of the chamber 10 into the user's mouth.
  • the user places the first end 12 of the chamber 10 in contact with an external source of a liquid and applies oral suction to the second end 14 of the chamber 10, such that the liquid is drawn into the first end 12 of the chamber 10 from the external source.
  • the external source of liquid is preferably a beverage, as described above for the device in which the chamber 10 contains a nicotine 16 granulate.
  • the beverage comprises flavorings and pH ranges as described above.
  • the nicotine 16 solution contained within the chamber 10 may itself contain the flavorings described above.
  • the solution is pre-formulated to fall within the aforementioned pH levels through use of an acid such as, for example, carbonic acid, citric acid, acetic acid, tartaric acid, maleic acid, ascorbic acid, adipic acid, or combinations thereof.
  • an acid such as, for example, carbonic acid, citric acid, acetic acid, tartaric acid, maleic acid, ascorbic acid, adipic acid, or combinations thereof.
  • Such pre-formulation to optimize flavoring and pH is especially desirable if the user will be drawing air, rather than liquid, through the first end of the chamber, such that the nicotine 16 solution contained in the chamber 10 is delivered without any liquid from an external source that might enhance palatability.
  • the chamber 10 of the device of the present invention further contains a retainer 18 for preventing release of nicotine 16 from the first end 12 of the chamber 10.
  • the term "retainer” refers to a disc, float, plug, or other restriction that blocks the diameter of the chamber 10 such that the nicotine 16 contained within the chamber 10 cannot be released from the first end 12 of the chamber 10.
  • the retainer 18 allows gas or liquid from an external source to enter the first end 12 of the chamber 10, but prevents release of nicotine 16 from the first end 12 of the chamber 10.
  • the retainer 18 also discourages release from the first end 12 of the chamber 10 of liquid drawn into the chamber 10 from an external source or contained within the chamber 10 as part of a pre-formulated solution of nicotine 16.
  • the retainer 18 may be fixed proximal to the first end 12 of the chamber 10. "Proximal to" the first end 12 of the chamber 10 means toward or at the first end 12 of the chamber 10. Alternatively, the retainer 18 may be transportable toward the second end 14 of the chamber 10. For example, the retainer 18 is transported toward the second end 14 of the chamber 10 as the user applies oral suction to the second end 14 of the chamber 10. Gas or liquid from an external source is drawn through the first end 12 of the chamber 10 into the device, and the nicotine 16 solution in the chamber 10 is delivered into the user's mouth.
  • the transportable retainer 18 assures that all of the nicotine 16 in the chamber 10 is cleanly delivered through the second end 14 of the chamber 10 into the user's mouth.
  • the second end 14 of the chamber 10 is constructed such that the retainer 18 itself is blocked from entering the user's mouth.
  • the diameter at the second end 14 of the chamber 10 may be smaller than the diameter elsewhere in the chamber 10 and smaller than the diameter of the retainer 18, such that the retainer 18 may pass from the first end 12 of the chamber 10 to the second end 14 of the chamber 10, but cannot pass through the second end 14 of the chamber 10 into the user's mouth.
  • the diameter at the second end 14 of the chamber 10 may be made smaller than the diameter elsewhere in the chamber 10 by a crimping of the chamber 10, a series of dimples in the circumference of the chamber 10, or a continuous indentation in the circumference of the chamber 10 at the second end 14 of the chamber 10.
  • a transportable retainer 18 is particularly useful when the device is prefilled with liquid, i.e., contains a pre-formulated solution of nicotine 16.
  • the retainer 18 may comprise a restriction and a plug.
  • restriction means that the diameter near the first end 12 of the chamber 10 is smaller than the diameter elsewhere in the chamber 10 and smaller than the diameter of the plug, such that the plug is contained within the chamber 10 and prevents release of nicotine 16 through the first end 12 of the chamber 10.
  • the restriction may result from, for example, a crimping of the chamber 10, a series of dimples in the circumference of the chamber 10, or a continuous indentation in the circumference of the chamber 10 near the first end 12 of the chamber 10.
  • the retainer 18 may alternatively comprise a particle barrier with apertures or slits that allow liquid to pass through the barrier when oral suction is applied to the second end 14 of the chamber 10.
  • a cap may be placed over the first end 12 of the chamber 10 prior to use to avoid any possible loss of nicotine 16 or entry of contaminants through the particle barrier apertures or slits.
  • the apertures must be small enough that nicotine 16 cannot pass through them and be released from the first end 12 of the chamber 10.
  • the slits are easier to manufacture and seal the chamber 10 more completely prior to use than the apertures do.
  • the barrier is made from a material such as fine mesh or porous paper that will retain the nicotine 16 in the chamber 10 but requires no barrier apertures or slits to allow liquid to be drawn into the chamber 10.
  • the barrier is preferably cone-shaped and located all the way at the first end 12 of the chamber 10.
  • the retainer 18 comprises a one-way plug or valve.
  • the plug or valve seals the first end 12 of the chamber 10 at atmospheric pressure.
  • the plug when suction is applied to the second end 14 of the chamber 10, the plug is deformed and permits liquid from an external source to flow around the plug and into the chamber 10 through the first end 12 of the chamber 10.
  • the plug preferably has a density of less than one, such that it is drawn toward the second end 14 of the chamber 10 when suction is applied to the second end 14 of the chamber 10 and the nicotine 16 contained within the chamber 10 is delivered into the mouth of the user.
  • suction is removed from the second end 14 of the chamber 10
  • the plug relaxes, seals the chamber 10, and remains stationary. Transportation of the plug all the way to the second end 14 of the chamber 10 indicates that the entire dose of nicotine 16 contained within the chamber 10 has been delivered.
  • the retainer 18 alternatively comprises a cylindrical body with at least one protrusion on its exterior surface. Liquid from an external source is drawn through or around the retainer 18 and into the chamber 10, but the protrusions prevent nicotine 16 solution from leaking through or around the sides of the retainer 18 and out of the first end 12 of the chamber 10.
  • the protrusions are fins, ridges, or rings which act as a seal for the chamber 10 and also create friction or drag between the retainer 18 and the chamber 10, which allows time for the liquid from the external source to mix with the nicotine 16 after passing through or around the retainer 18.
  • the retainer 18 of the present invention may be made from, for example, thermoplastic materials or low or high density foam materials such as, without limitation, ethylene vinyl acetate copolymers, polyolefins such as polyethylene, polypropylene, and the like, or closed cell foam.
  • the retainer 18 may comprise, for example, a compressible plug of bonded fibers.
  • the fibers may be polymeric fibers, such as polyolefm fibers with or without a polyester core, polyester, cellulose acetate, nylon, felt, or cotton.
  • the uncompressed fiber plug preferably has a diameter slightly larger than the diameter of the chamber 10. Thus, after insertion in the chamber 10, the plug seals and prevents the release of nicotine 16 from the chamber 10, but still allows liquid to be drawn into the chamber 10 when oral suction is applied to the second end 14 of the chamber 10.
  • the chamber 10 of the device of the present invention preferably also contains a removable end cap 20 or seal located at the second end 14 of the chamber 10.
  • the removable end cap 20 or seal prevents the nicotine 16 granulate or pre-formulated nicotine 16 solution contained within the chamber 10 from being released through the second end 14 of the chamber 10 during shipping and storage of the device.
  • the user removes the end cap 20 or seal from the second end 14 of the chamber 10 so that the nicotine 16 granulate or pre-formulated nicotine 16 solution contained within the chamber 10 may be delivered through the second end 14 of the chamber 10 into the user's mouth.
  • Materials for making the end cap 20 or seal of the present invention may include, without limitation, paper, foil, plastic such as propylene/styrene copolymers, polypropylene, high density polyethylene, low density polyethylene, ethylene vinyl acetate copolymer, and the like.
  • the device itself, may comprise a flavoring, such that it tastes pleasant for chewing as, before, or after the nicotine dose has been delivered.
  • the flavoring may be, for example, sugar, cinnamon, spearmint, peppermint, wintergreen, bubble gum, fruit, chocolate, anise, nut, coffee, tobacco, or combinations thereof.
  • the flavoring is selected from the group consisting of spearmint, peppermint, wintergreen, and cinnamon.
  • the device as described in detail above provides the novel synergistic combination of oral and tactile stimulation along with a controlled dose of nicotine in non-irritating solution form.
  • Smokers attempting to stop smoking may use the device as an aid that can satisfy nicotine needs and at the same time prevent cigarette cravings by providing a substitute for the hand-to- mouth behavioral component of smoking.
  • the synergistic combination of the present invention provides an important new method for reducing the incidence of tobacco smoking in smokers who appreciate the health risks of smoking and wish to stop.
  • EXAMPLE 1 Safety and Pharmacokinetics Study 1.
  • Device Nicotine is administered orally using a straw-like smoking cessation device of the invention as shown in FIG. 1.
  • the chamber 10 is a plastic drinking straw.
  • the retainer 18 is a filter at the first end 12 of the straw.
  • the user places the first end 12 of the device in a glass of apple juice and applies oral suction to the second end 14 of the device, such that the juice and nicotine 16 are delivered into the user's mouth.
  • the nicotine 16 in the device is in the form of coated sugar spheres of nicotine bitartrate having a diameter of approximately 500 micrometers.
  • the nicotine spheres are prepared by spraying nicotine bitartrate dihydrate with a binder onto sugar spheres and applying a film coating.
  • a Wurster processing unit particles are suspended in air using a controlled airflow system and a coating suspension is added at a controlled rate via a pneumatically atomized nozzle. As atomized droplets of the coating solution contact the particles, they spread and coalesce on the particle surface. Excess moisture from the applied liquid evaporates in the apparatus, leaving a coated dry substance. Mixing of the coating suspension occurs throughout the manufacturing process to ensure uniformity of the suspension.
  • EXAMPLE 2 Efficacy Study In a double blind study, three hundred healthy adult smokers who wish to give up smoking use the smoking cessation device as described in Example 1 to deliver nicotine or placebo over a ten week period. Each device contains 5-10 mg of nicotine or placebo. Subjects are instructed to use the device as needed for smoking urges, but not to exceed 12 doses per day. Patients are concurrently enrolled in a counseling program to provide behavioral support for smoking cessation. Smoking abstinence data are collected during the last eight weeks of treatment, serving as the primary endpoint. Abstinence is defined as four weeks of continuous abstinence from smoking during the study period. Subjects have weekly clinic visits for monitoring plasma levels of nicotine and cotinine, vital signs, adverse events, and patient's assessment of cigarette cravings. Baseline and endpoint clinical chemistry, hematology, urinalysis, and ECG are also monitored.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dispositif d'apport oral de nicotine et procédé d'utilisation dudit dispositif pour réduire l'incidence de la tabagie sur une personne. Ledit dispositif possède une chambre tubulaire (10) dotée d'une première extrémité (12) adaptée pour l'introduction de liquide ou de gaz provenant d'une source externe et une seconde extrémité (14) adaptée pour l'aspiration orale. La chambre contient de la nicotine (16) et un élément de retenue (18) destiné à empêcher la fuite de nicotine (16) par la première extrémité (12) de la chambre (10). Ce dispositif permet l'apport de nicotine (16) sous la forme d'une solution non irritante.
PCT/US2001/051239 2000-11-03 2001-10-25 Dispositif et procede pour arreter de fumer WO2002038208A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002540788A JP2004512907A (ja) 2000-11-03 2001-10-25 禁煙用の装置および方法
CA002427283A CA2427283A1 (fr) 2000-11-03 2001-10-25 Dispositif et procede pour arreter de fumer
AU2002234179A AU2002234179A1 (en) 2000-11-03 2001-10-25 Device and method for the cessation of smoking
EP01985209A EP1331960A2 (fr) 2000-11-03 2001-10-25 Dispositif et procede pour arreter de fumer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24549000P 2000-11-03 2000-11-03
US60/245,490 2000-11-03

Publications (3)

Publication Number Publication Date
WO2002038208A2 true WO2002038208A2 (fr) 2002-05-16
WO2002038208A3 WO2002038208A3 (fr) 2003-05-15
WO2002038208A9 WO2002038208A9 (fr) 2003-11-06

Family

ID=22926878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/051239 WO2002038208A2 (fr) 2000-11-03 2001-10-25 Dispositif et procede pour arreter de fumer

Country Status (6)

Country Link
US (1) US20020059939A1 (fr)
EP (1) EP1331960A2 (fr)
JP (1) JP2004512907A (fr)
AU (1) AU2002234179A1 (fr)
CA (1) CA2427283A1 (fr)
WO (1) WO2002038208A2 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037313A2 (fr) * 2001-10-31 2003-05-08 Recovery Pharmaceuticals, Inc. Methodes de traitement de la toxicomanie
DE10228173A1 (de) * 2002-03-27 2003-10-09 Gruenenthal Gmbh System zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
DE10228192A1 (de) * 2002-06-24 2004-01-15 Grünenthal GmbH Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
DE10228171A1 (de) * 2002-06-24 2004-01-22 Grünenthal GmbH Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
DE10228176A1 (de) * 2002-06-24 2004-01-22 Grünenthal GmbH Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
DE10228179A1 (de) * 2002-06-24 2004-01-22 Grünenthal GmbH Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
WO2004041283A1 (fr) * 2002-10-31 2004-05-21 Recovery Pharmaceuticals, Inc. Procede et dispositif pour traiter des dependances combinees
DE10308175A1 (de) * 2003-02-25 2004-09-02 Grünenthal GmbH Darreichungsform und Kit zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
EP1461013A2 (fr) * 2001-12-10 2004-09-29 Marshall A. Thompson Procede de production d'une composition a base de nicotine
WO2017051017A1 (fr) * 2015-09-25 2017-03-30 Philip Morris Products S.A. Formulation de pré-vaporisation pour réguler l'acidité dans un dispositif de vapotage électronique
US10098376B2 (en) 2003-11-07 2018-10-16 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US10172901B2 (en) 2014-06-27 2019-01-08 British American Tobacco (Investments) Limited Powder for delivery to the oral cavity
US10266287B2 (en) 2013-06-03 2019-04-23 Essentra Filter Products Development Co. Pte. Ltd Method of manufacture of a dispenser
US10730688B2 (en) 2013-06-03 2020-08-04 Essentra Filter Products Development Co. Pte. Ltd Dispenser for particulate material
US10945454B2 (en) 2003-11-07 2021-03-16 U.S. Smokeless Tobacco Company Llc Tobacco compositions

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050013886A1 (en) * 2003-07-18 2005-01-20 Dawe Marc Charles Cigarette substitute and aid to quit tobacco use
US20050045197A1 (en) * 2003-08-28 2005-03-03 Gelder Steven K. Multiple drug delivery system & method
US20050236006A1 (en) * 2004-04-24 2005-10-27 Anderson Cowan Smoking cessation devices, methods of use and methods of conducting business therewith
US20060034886A1 (en) * 2004-07-23 2006-02-16 Ward Bennett C Bonded fiber structures for use in controlling fluid flow
DE102005046460B4 (de) * 2004-09-24 2008-08-21 Christian Wendt Saugstäbchen für die simultane Aufnahme von Getränken und flüchtigen Aromen
US7766018B2 (en) * 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
CA2634673C (fr) * 2005-12-22 2015-09-29 Philip Morris Products S.A. Dispositif inhalateur avec feuille impermeable a l'air
US7766019B2 (en) * 2006-07-21 2010-08-03 Gp Technologies, Inc. Porous plastic smoking cessation devices
US20080230078A1 (en) * 2007-03-19 2008-09-25 Oby George Tolman Method of smoking cessation
US7845359B2 (en) 2007-03-22 2010-12-07 Pierre Denain Artificial smoke cigarette
FR2920308B1 (fr) * 2007-09-05 2011-02-25 Unither Dev Forme pharmaceutique pour l'administration par voie orale de principes actifs.
US8991402B2 (en) 2007-12-18 2015-03-31 Pax Labs, Inc. Aerosol devices and methods for inhaling a substance and uses thereof
JP4817200B2 (ja) * 2008-07-31 2011-11-16 有限会社静岡園 タバコ型薬品吸入具
US20100200008A1 (en) * 2009-02-09 2010-08-12 Eli Taieb E-Cigarette With Vitamin Infusion
USD642330S1 (en) 2009-10-26 2011-07-26 Jeffrey Turner Delivery device
US9050431B2 (en) 2010-10-18 2015-06-09 Jeffrey turner Device for dispensing a medium
US9545489B2 (en) 2010-10-18 2017-01-17 Jeffrey Turner Device for dispensing a medium
CN102039108B (zh) * 2011-01-13 2012-04-25 广州市戴文高分子材料科技有限公司 一种香精微胶囊的制备方法
WO2013088112A2 (fr) * 2011-12-16 2013-06-20 Indosys Limited Cartouche de dose unitaire de médicament et dispositif d'administration
US9854839B2 (en) * 2012-01-31 2018-01-02 Altria Client Services Llc Electronic vaping device and method
RU2659887C2 (ru) 2013-05-06 2018-07-04 Джуул Лэбз, Инк. Составы на основе солей никотина для аэрозольных устройств и способы их применения
WO2015009913A1 (fr) 2013-07-19 2015-01-22 Altria Client Services Inc. Procédés et systèmes pour incorporer de la nicotine dans des produits à usage oral
WO2015009862A2 (fr) 2013-07-19 2015-01-22 Altria Client Services Inc. Formulation d'aérosol liquide pour un article à fumer électronique
IL308151A (en) 2013-12-05 2023-12-01 Juul Labs Inc Liquid preparations of nicotine for spray devices and methods
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
GB2532062A (en) * 2014-11-07 2016-05-11 Nicoventures Holdings Ltd Container
US11838997B2 (en) 2018-11-05 2023-12-05 Juul Labs, Inc. Cartridges for vaporizer devices
CN109965629A (zh) * 2019-03-20 2019-07-05 深圳市康道科技集团有限公司 饮品的混合口味食用方法
CN112167701A (zh) * 2020-10-14 2021-01-05 云南氪莱铂科技有限公司 一种抽泡两用发烟体颗粒、制备的加热不燃烧制品及应用
USD950841S1 (en) 2020-12-14 2022-05-03 ARK Industries Smoking cessation device

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365102A (en) * 1965-12-10 1968-01-23 Willene M. Castleberry Means for holding, supporting and dispensing liquid comestibles
US4284089A (en) * 1978-10-02 1981-08-18 Ray Jon P Simulated smoking device
US4993436A (en) * 1989-12-21 1991-02-19 Bloom Jr Walter L Aspirating and volatilizing liquid dispenser
WO1999055371A1 (fr) * 1998-04-30 1999-11-04 Duke University Solution a base de nicotine
US6041789A (en) * 1999-01-28 2000-03-28 K&B Technologies, L.L.C. Cigarette substitute device and composition for use therein
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
US6106845A (en) * 1995-07-21 2000-08-22 Alza Corporation Oral delivery of discrete units

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365102A (en) * 1965-12-10 1968-01-23 Willene M. Castleberry Means for holding, supporting and dispensing liquid comestibles
US4284089A (en) * 1978-10-02 1981-08-18 Ray Jon P Simulated smoking device
US4993436A (en) * 1989-12-21 1991-02-19 Bloom Jr Walter L Aspirating and volatilizing liquid dispenser
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
US6106845A (en) * 1995-07-21 2000-08-22 Alza Corporation Oral delivery of discrete units
WO1999055371A1 (fr) * 1998-04-30 1999-11-04 Duke University Solution a base de nicotine
US6041789A (en) * 1999-01-28 2000-03-28 K&B Technologies, L.L.C. Cigarette substitute device and composition for use therein

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037313A3 (fr) * 2001-10-31 2003-09-25 Recovery Pharmaceuticals Inc Methodes de traitement de la toxicomanie
WO2003037313A2 (fr) * 2001-10-31 2003-05-08 Recovery Pharmaceuticals, Inc. Methodes de traitement de la toxicomanie
EP1461013A4 (fr) * 2001-12-10 2009-04-08 Marshall A Thompson Procede de production d'une composition a base de nicotine
EP1461013A2 (fr) * 2001-12-10 2004-09-29 Marshall A. Thompson Procede de production d'une composition a base de nicotine
DE10228173A1 (de) * 2002-03-27 2003-10-09 Gruenenthal Gmbh System zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
DE10228192A1 (de) * 2002-06-24 2004-01-15 Grünenthal GmbH Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
DE10228171A1 (de) * 2002-06-24 2004-01-22 Grünenthal GmbH Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
DE10228176A1 (de) * 2002-06-24 2004-01-22 Grünenthal GmbH Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
DE10228179A1 (de) * 2002-06-24 2004-01-22 Grünenthal GmbH Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
WO2004041283A1 (fr) * 2002-10-31 2004-05-21 Recovery Pharmaceuticals, Inc. Procede et dispositif pour traiter des dependances combinees
DE10308175A1 (de) * 2003-02-25 2004-09-02 Grünenthal GmbH Darreichungsform und Kit zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen
US10098376B2 (en) 2003-11-07 2018-10-16 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US10765140B2 (en) 2003-11-07 2020-09-08 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US10945454B2 (en) 2003-11-07 2021-03-16 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US10266287B2 (en) 2013-06-03 2019-04-23 Essentra Filter Products Development Co. Pte. Ltd Method of manufacture of a dispenser
US10730688B2 (en) 2013-06-03 2020-08-04 Essentra Filter Products Development Co. Pte. Ltd Dispenser for particulate material
US10172901B2 (en) 2014-06-27 2019-01-08 British American Tobacco (Investments) Limited Powder for delivery to the oral cavity
WO2017051017A1 (fr) * 2015-09-25 2017-03-30 Philip Morris Products S.A. Formulation de pré-vaporisation pour réguler l'acidité dans un dispositif de vapotage électronique
US10327472B2 (en) 2015-09-25 2019-06-25 Altria Client Services Llc Pre-vaporization formulation for controlling acidity in an e-vaping device

Also Published As

Publication number Publication date
CA2427283A1 (fr) 2002-05-16
AU2002234179A1 (en) 2002-05-21
EP1331960A2 (fr) 2003-08-06
JP2004512907A (ja) 2004-04-30
US20020059939A1 (en) 2002-05-23
WO2002038208A9 (fr) 2003-11-06
WO2002038208A3 (fr) 2003-05-15

Similar Documents

Publication Publication Date Title
US20020059939A1 (en) Device and method for the cessation of smoking
US20030111088A1 (en) Device and method for treating combination dependencies
US6595209B1 (en) Dry powder delivery system
US5893371A (en) Non-nicotine smoking cessation aid
US20050236006A1 (en) Smoking cessation devices, methods of use and methods of conducting business therewith
AU2016247916B2 (en) Flavoring element for an inhalation device
WO1991001656A1 (fr) Moyen utilise pour aider a arreter de fumer ou utilise dans des zones non fumeur
BR112019006822A2 (pt) Dispositivos, sistemas e métodos para distribuição de voláteis derivados do café
EP0745380B1 (fr) Substitut de tabac
US20100256197A1 (en) Nicotine Dissolving Film With Or Without Menthol
US20180071274A1 (en) Medical product for reducing and/or eliminating symptoms of nicotine withdrawal
WO2004041283A1 (fr) Procede et dispositif pour traiter des dependances combinees
US20050045197A1 (en) Multiple drug delivery system & method
AU703023B2 (en) Dry powder delivery system
US20180042912A1 (en) Medical product and method for eliminating symptoms of nicotine withdrawal
Roopchandani et al. Smoking cessation aids
US20130327328A1 (en) Apparatus and methods for direct inhalation of scents and medicines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2427283

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002234179

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002540788

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001985209

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001985209

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2001985209

Country of ref document: EP